Eribulin Injectable is a highly potent anticancer product, requiring both API and formulation manufacturing to be conducted in high-containment facilities. This API is particularly challenging to manufacture, involving 64 synthetic steps and the establishment of 19 chiral centers, demonstrating a highly sophisticated chemical synthesis and manufacturing capability. Europe is the third major pharmaceutical market Eribulin injectable received approval, following Taiwan and the United States. 

This approval highlights Formosa Laboratories’ strong expertise in the development and manufacturing of highly potent oncology products and sterile injectables, further strengthening the company’s presence in the global high-value oncology generic market.